LOGIN  |  REGISTER
Terns Pharmaceuticals
Cue Biopharma

American Oncology Network Announces Second Quarter 2024 Earnings Release Date and Conference Call

July 31, 2024 | Last Trade: US$4.85 0.86 21.55

FORT MYERS, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (“AON” or the “Company”) (OTCQX: AONC), one of the fastest growing community-based oncology practices, announced today that the Company will release its second quarter 2024 financial results on Wednesday, August 14, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on the same day.

To access the call through a conference line, dial 1-877-704-4453 or for international callers, 1-201-389-0920. The passcode for the live call is 13748211. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The Access ID for the replay call is 13748211. The replay will be available until Wednesday, August 21, 2024.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at investors.aoncology.com.

About American Oncology Network

American Oncology Network (AON) (OTCQX: AONC) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 240 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. Learn more at www.AONcology.com

Investor Contact:
David Afshar, Chief Financial Officer and Chief Operating Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB